Equity Profile

TVTX

Travere Therapeutics, Inc.

Health CareBiotechnology$5.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $5 billion, it plays a crucial role in addressing unmet medical needs in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations by 116.78%. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continue focusing on innovative treatments for rare diseases.
Maintain strong financial performance as evidenced by recent EPS surprises.
Provide updates on ongoing clinical trials and product pipeline.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Travere's upcoming earnings, given its strong history of beating EPS estimates. However, there are concerns about revenue growth and market conditions.

Bull Case

If Travere continues its trend of strong EPS surprises, it could indicate robust demand for its therapies, leading to further stock price appreciation.

Bear Case

On the other hand, if revenue growth fails to meet expectations, it could raise doubts about the company's future prospects and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Travere's strong history of EPS surprises, this figure will be crucial in determining market sentiment and stock reaction.

How is revenue growth tracking compared to previous quarters?

Investors will closely watch revenue figures to assess the company's ability to sustain growth and meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to sustain its earnings momentum despite potential revenue growth concerns, as historical performance suggests strong resilience.

Supporting Evidence

Travere has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors anticipate a notable reaction.

The historical average move following earnings beats has been positive, indicating investor confidence.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment in favor of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Travere can maintain its impressive earnings performance amidst potential revenue growth challenges.

Bull Confirmed If

An EPS of $0.10 or higher would confirm strong financial performance and support bullish sentiment.

Bear Confirmed If

An EPS below $0.00 could signal potential issues with profitability and lead to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around +0.68%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest management's commentary.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around -1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new therapies.
2Management's commentary on revenue growth strategies and market conditions.
3Details on any new partnerships or collaborations in the pipeline.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on EPS and revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations by 116.78%. The stock reacted positively, gaining 1.79% the following day.

Management Promises & Guidance

Continue focusing on innovative treatments for rare diseases.
Maintain strong financial performance as evidenced by recent EPS surprises.
Provide updates on ongoing clinical trials and product pipeline.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Travere's upcoming earnings, given its strong history of beating EPS estimates. However, there are concerns about revenue growth and market conditions.

Bull Case

If Travere continues its trend of strong EPS surprises, it could indicate robust demand for its therapies, leading to further stock price appreciation.

Bear Case

On the other hand, if revenue growth fails to meet expectations, it could raise doubts about the company's future prospects and negatively impact the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Travere's strong history of EPS surprises, this figure will be crucial in determining market sentiment and stock reaction.

How is revenue growth tracking compared to previous quarters?

Investors will closely watch revenue figures to assess the company's ability to sustain growth and meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Travere's ability to sustain its earnings momentum despite potential revenue growth concerns, as historical performance suggests strong resilience.

Supporting Evidence

Travere has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors anticipate a notable reaction.

The historical average move following earnings beats has been positive, indicating investor confidence.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment in favor of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Travere can maintain its impressive earnings performance amidst potential revenue growth challenges.

Bull Confirmed If

An EPS of $0.10 or higher would confirm strong financial performance and support bullish sentiment.

Bear Confirmed If

An EPS below $0.00 could signal potential issues with profitability and lead to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests a potential stock increase of around +0.68%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest management's commentary.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around -1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new therapies.
2Management's commentary on revenue growth strategies and market conditions.
3Details on any new partnerships or collaborations in the pipeline.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on EPS and revenue expectations for the next quarter.